Nuwellis announces non-binding letter of intent to acquire Rendiatech

Nuwellis, Inc. (NASDAQ:NUWE), a medical device company with a market capitalization of $3.3 million and annual revenue of $8.3 million, announced Tuesday that it has entered into a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company. Rendiatech specializes in real-time urine flow and acute kidney injury monitoring technologies. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 2.16, indicating sufficient assets to cover short-term obligations.

According to a press release statement, the proposed acquisition is intended to expand Nuwellis’s current technology platform beyond ultrafiltration, with the potential addition of continuous renal health monitoring technologies. These technologies are designed to provide clinicians with earlier insight into fluid status and kidney function.

Both companies are currently engaged in a due diligence process. If an agreement is reached, the transaction is expected to close in the fourth quarter of 2025, subject to final Board approval and other closing conditions.

Nuwellis is based in Eden Prairie, Minnesota, and is incorporated in Delaware. Its common stock is traded on the Nasdaq Capital Market under the symbol NUWE.

This information is based on a statement included in a recent SEC filing.

In other recent news, Nuwellis Inc. reported a challenging second quarter of 2025, with a 21% year-over-year decline in total revenue, amounting to CAD $1.7 million. The company also faced a significant net loss during this period. Despite these financial hurdles, Nuwellis is concentrating on strategic initiatives to enhance its financial health and broaden its market presence. Additionally, Nuwellis announced it has signed a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli medical device company. This proposed acquisition aims to expand Nuwellis’ fluid management technology platform by incorporating Rendiatech’s Clarity RMS, a critical care monitoring system that has received FDA clearance. Rendiatech is also in the process of developing Clarity Prime, a next-generation system to further advance urine monitoring capabilities. These recent developments underscore Nuwellis’ efforts to strengthen its position in the medical device industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.